Skip to content
mapperlab
← Dashboard
Stock

SOLV

SOLVENTUM CORPORATION
Health CareHealth Care TechnologyLatest close $765 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
3

Marquee-fund ownership over time

Aug 14, 2024Feb 14, 2025Aug 14, 2025May 15, 2026
Now
5

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors re-entered$58$76+32%
D.E. Shaw$58$76+32%
AQR Capital Management$58$76+32%
Millennium Management re-entered$58$76+32%
Bridgewater Associates re-entered$70$76+9%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments→ $74+1%
Point72 Asset Management 2× in & out→ $74+1%
Renaissance Technologies 2× in & out→ $74+5%
Soros Fund Management→ $68+18%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Solventum Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
29
Filings · last 90d
49
Total on file
124
Recent SEC buffer
Most recent
May 18, 2026

30d / 90d windows measured from May 18, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 124 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · SOLVENTUM CORPORATION

Annual figures sourced directly from SOLVENTUM CORPORATION's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$8.33B
FY2025+1% YoY
Net income
$1.56B
FY2025+225% YoY
EPS (diluted)
$8.88
FY2025+222% YoY
Free cash flow(?)
-$10M
FY2025-101% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Solventum Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ1 2026Q2 2026$74$74+1%
Point72 Asset ManagementQ1 2026Q2 2026$74$74+1%
Bridgewater AssociatesQ4 2025open$75$76+1%
Millennium ManagementQ3 2025open$73$76+4%
Renaissance TechnologiesQ2 2025Q2 2026$71$74+5%
Citadel AdvisorsQ1 2025open$74$76+3%
Point72 Asset ManagementQ4 2024Q1 2025$68$74+9%
Renaissance TechnologiesQ4 2024Q1 2025$70$74+6%
Bridgewater AssociatesQ4 2024Q3 2025$70$74+6%
Citadel AdvisorsQ3 2024Q4 2024$58$68+18%
Soros Fund ManagementQ3 2024Q4 2024$58$68+18%
D.E. ShawQ3 2024open$58$76+32%
AQR Capital ManagementQ3 2024open$58$76+32%
Millennium ManagementQ3 2024Q2 2025$58$73+26%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.